Trial Profile

Effectiveness and Safety of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia: an Observational Study

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 08 Oct 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atorvastatin (Primary) ; Bempedoic acid (Primary) ; Bempedoic acid/ezetimibe (Primary) ; Rosuvastatin (Primary)
Indications Dyslipidaemias; Hypercholesterolaemia
Focus Therapeutic Use
Acronyms TRICONOS
Sponsors Daiichi Sankyo Europe

30 Sep 2026 Status changed from recruiting to active, no longer recruiting.
14 May 2025 Planned End Date changed from 1 Feb 2027 to 31 Jan 2028.
14 May 2025 Planned primary completion date changed from 1 Feb 2027 to 31 Jul 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com